GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

Running, not enrolling · Phase 1/Phase 2

Conditions studied: Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Ductal Adenocarcinoma (PDAC)

In brief

The goal of this trial is to learn about the antibody GEN1042 when it is used alone and when it is used together with another antibody cancer drug, pembrolizumab (with or without chemotherapy), for treatment of participants with certain types of cancer.

Key facts

Study ID
NCT04083599
Run by
Genmab
People needed
350
Starts
2019-09-17
Expected to finish
2027-01-01
Last updated by the study team
2026-08-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.